Vimarsana
Biggest News Aggregation in the World

Page 33 - Managed Care News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Managed Care. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Managed Care Today - Breaking & Trending Today

Health Equity and Access Weekly Roundup: January 6, 2023 - Vimarsana News

Health Equity and Access Weekly Roundup: January 6, 2023

The Center on Health Equity and Access delivers current news, highlights research advancements, and continuous initiatives focused on addressing health care disparities and improving overall accessibility to exceptional care.

Source: ajmc.com
Centene Co. (NYSE:CNC) Shares Sold by Bailard Inc. - Vimarsana News

Centene Co. (NYSE:CNC) Shares Sold by Bailard Inc.

Bailard Inc. trimmed its position in Centene Co. (NYSE:CNC – Free Report) by 4.0% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 16,308 shares of the company’s stock after selling 677 shares during the period. Bailard Inc.’s holdings in Centene were worth $1,123,000 at the end […]

From Chaos to Clarity: The Power of Cloud Governance - Vimarsana News

From Chaos to Clarity: The Power of Cloud Governance

Proper cloud governance is essential for a well-oiled cloud computing machine to dodge risks and keep operational performance in top gear.

Centene Co. (NYSE:CNC) Shares Bought by Vantage Investment Partners LLC - Vimarsana News

Centene Co. (NYSE:CNC) Shares Bought by Vantage Investment Partners LLC

Vantage Investment Partners LLC lifted its holdings in Centene Co. (NYSE:CNC – Free Report) by 11.2% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 433,492 shares of the company’s stock after purchasing an additional 43,548 shares during the period. Centene comprises 3.9% […]

Sarepta Therapeutics Seeks to Expand Delandistrogene Moxeparvovec Indications - Vimarsana News

Sarepta Therapeutics Seeks to Expand Delandistrogene Moxeparvovec Indications

Delandistrogene moxeparvovec-rokl (Elevidys; Sarepta Therapeutics) is currently approved to treat Duchenne muscular dystrophy in 4- and 5-year-old patients who have a confirmed DMD gene mutation.

Source: ajmc.com